Tisagenlecleucel Demonstrates Real-World Clinical Benefit in DLBCL

Gina Columbus @ginacolumbusonc
Published: Tuesday, Dec 10, 2019

Samantha M. Jaglowski, MD, associate professor in the Department of Internal Medicine, Ohio State University Comprehensive Cancer Center

Samantha M. Jaglowski, MD

The CD19-directed CAR T-cell therapy tisagenlecleucel (Kymriah) demonstrated similar real-world efficacy and safety findings to that of the pivotal JULIET trial in the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, according to an analysis of the PICTOR (CTL019B2401)/CIBMTR SC 17-08 registry presented at the 2019 ASH Annual Meeting.1

Results showed that the best overall response rate (ORR) was 58%, which included a complete response (CR) rate of 40% and a partial response (PR) rate of 18%.  

The efficacy findings are overall comparable with the updated data from the phase II JULIET trial, which were published in the New England Journal of Medicine earlier this year. Specifically, in JULIET, the ORR with the agent was 52%, with a CR rate of 40% and a PR rate of 12%.2

“Tisagenlecleucel therapy real-world evidence confirms the efficacy data reported in the JULIET study,” Samantha M. Jaglowski, MD, associate professor in the Department of Internal Medicine, Ohio State University Comprehensive Cancer Center–James, said in a presentation during the conference. “Additionally, the safety profile [of the product] appears more favorable in the registry compared with the pivotal study.”

In May 2018, the FDA approved tisagenlecleucel for use in adult patients with relapsed/refractory large B-cell lymphoma—including DLBCL, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma—after ≥2 lines of systemic therapy.

The approval was based on earlier phase II JULIET findings, in which tisagenlecleucel reached an ORR of 50% (95% CI, 38%-62%) in adult patients with relapsed/refractory DLBCL.3 The CR rate was 32% and the PR rate was 18%; the median duration of response (DOR) had not yet been reached.

The Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry was created to capture long-term data from patients who have received CAR T-cell therapy. In September 2018, the CIBMTR and Novartis, the developer of tisagenlecleucel, created this post-marketing study of tisagenlecleucel in the real-world setting to collect long-term safety and efficacy data from patients receiving the CAR T-cell therapy.

The registry plans to follow patients with lymphoma (n = 1500) and acute lymphoblastic leukemia (n = 1000) who have been treated with tisagenlecleucel for 15 years; this includes patients receiving an out-of-specification (OOS) product. The first patient entered on the registry was infused in June 2018. Recommended visit assessments were pre-infusion, at months 3, 6, 12, and annually after infusion.

Efficacy and safety data were collected from patients with ≥3 months of follow-up. Additionally, cytokine release syndrome (CRS) as per the consensus American Society for Transplantation and Cellular Therapy criteria and neurotoxicity via the Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) scale were reported. Tisagenlecleucel’s manufacturing product characteristics and cell product characterization by immunophenotyping were compared with clinical outcomes obtained in the registry. Investigators used descriptive summaries and univariate logistic regression analyses to evaluate the association of cells administered, cell viability, potency, transduction efficiency to overall response, CRS, and ICANS grade.

To date, 39 centers contributed findings for 116 patients with relapsed/refractory DLBCL through the registry. The efficacy data set included 80 patients, 75 of which were in a manufacturing set; safety data were available for 83 patients, 77 of which were in a manufacturing set. The total manufacturing set includes 102 patients.

The median age of the participants included in the analysis was 65 years (range, 15-89); in JULIET, Jaglowski noted that the median age was 56 years (range, 22-74). Sixty percent of patients were male and most patients were white (85.7%). Furthermore, 34.3%, 47.1%, 4.3%, and 14.3% of patients had an ECOG performance status of 0, 1, 2, and not reported, respectively. Forty-one percent of patients had double- or triple-hit lymphoma and 27% had transformed lymphoma; 32% and 61% of patients had refractory and relapsed disease, respectively. Twenty-four percent of patients had undergone prior autologous stem cell transplant; allogeneic stem cell transplant occurred in 4% of patients.

The median time from diagnosis of DLBCL to CAR T-cell therapy was 15 months, and the median time from manufacturing start to infusion was 32 days. All patients were treated with the FDA-approved dose of tisagenlecleucel of 0.6 to 6 x 108; the median dose was 1.7 x 108 CAR+ viable T cells (range, 0.4-6.8 x 108).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication